Confo Therapeutics announces exclusive, worldwide license agreement with VIB for Powerful Novel Structure Determination Technology

News
- 03/01/2019
  • Confo Therapeutics secures exclusive, worldwide license to new proprietary Megabody technology for GPCRs
  • Megabody scaffold extends the utility of Confo® bodies to cryo-EM, without affecting their conformation selectivity
  • Two Megabody publications in this week’s issue of Nature reveal unprecedented high-resolution structure of the GABAA receptor

 

Ghent, Belgium: 3 January 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has entered into an agreement with VIB, a life sciences research institute in Flanders, Belgium, for an exclusive, worldwide license to VIB’s ‘Megabody’ technology.

Megabodies are novel antigen-binding chimeric proteins which are ideally suited for three-dimensional structural analysis of proteins via high-resolution cryo-electron microscopy (cryo-EM).

The Megabody technology enabled an international team of scientists, including Confo Therapeutics’ founder, Prof Jan Steyaert of the VIB-VUB Center for Structural Biology, to produce high resolution cryo-EM structures of the native human GABAA receptor in complex with common drugs for the first time – published in this week’s Nature, see full references below.

More info on Confo Therapeutics’ website